1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

which was presented at the American Society of Clinical Oncology 2024 annual meeting, European Hematology Association 2024 meeting, and published in The New England Journal of Medicine. IMROZ is the ...

The protein expression technology market is projected to be worth USD 2,675.20 million in 2023. The market is likely to reach ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

In October 2024, we provided updated results from our IMMUNOCERV Phase 2 clinical trial in locally advanced cervical cancer patients treated with Versamune ® HPV and chemoradiotherapy presented at the ...

Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that ...

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer ...

Dr. Yuan, of the No.1 Hospital of Guangzhou University of Chinese Medicine, said: "More research is needed ... The findings ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...